Ticker Details
Spero Therapeutics, Inc. Spero Therapeutics Inc is a multi asset clinical stage biopharmaceutical company. It is focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.
IPO Date:	November 2, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$122.75M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.25 | 3.55%
Avg Daily Range (30 D):	$0.11 | 4.19%
Avg Daily Range (90 D):	$0.08 | 3.34%

Institutional Daily Volume
Avg Daily Volume:	.59M
Avg Daily Volume (30 D):	1.4M
Avg Daily Volume (90 D):	.75M

Trade Size
Avg Trade Size (Sh.):	247
Avg Trade Size (Sh.) (30 D):	214
Avg Trade Size (Sh.) (90 D):	182

Institutional Trades
Total Institutional Trades:	101
Avg Institutional Trade:	$1.65M
Avg Institutional Trade (30 D):	$.62M
Avg Institutional Trade (90 D):	$.6M
Avg Institutional Trade Volume:	.2M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.87M
Avg Closing Trade (30 D):	$.62M
Avg Closing Trade (90 D):	$.62M
Avg Closing Volume:	298.86K

News

Jun 17, 2026 @ 5:29 PM GSK, Spero Win FDA Nod For First-Ever Oral Carbape... Source: Vandana Singh

Nov 28, 2025 @ 1:00 PM Spero Therapeutics Announces Inducement Grant Unde... Source: Spero Therapeutics

Jan 10, 2025 @ 12:00 PM Spero Therapeutics Provides Business Update and An... Source: Spero Therapeutics

Jul 3, 2024 @ 5:07 PM Spero Therapeutics Announces Inducement Grant Unde... Source: N/A

Jun 24, 2024 @ 1:07 PM Denali Therapeutics (DNLI) Moves 5.8% Higher: Will... Source: Zacks Equity Research

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$.27	$-.13	$.56
Diluted EPS	$.27	$-.13	$.56
Revenue	$61.19M	$.26M	$41.3M
Gross Profit
Net Income / Loss	$15.24M	$-7.2M	$31.52M
Operating Income / Loss	$13.51M	$-7.54M	$31.41M
Cost of Revenue
Net Cash Flow	$7.24M	$15.86M	$-8.35M
PE Ratio